Concepedia

Publication | Closed Access

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

DOI

139

Citations

11

References

2014

Year

Mikaël Cohen, Élisabeth Maillart, Ayman Tourbah, J. de Sèze, Sandra Vukusic, David Brassat, Olivier Anne, Sandrine Wiertlewski, William Camu, Sylvie Courtois,
JAMA Neurology

Abstract

In this study, switching from natalizumab to fingolimod was associated with a risk of MS reactivation during the WP or shortly after fingolimod initiation. The WP should be shorter than 3 months.

References

YearCitations

Page 1